October 25, 2017
Wednesday, October 25, 2017
A scientific team at the University of Rochester is using innovative technology to discover preventative treatments for salivary gland radiation damage typical for head and neck cancer patients—and recently received a $3.8 million National Institutes of Health grant to support their investigation.
Cancer patients can lose salivary gland function during treatment for head and neck tumors. The irreversible damage, which prevents patients from producing saliva, often results in permanent dry mouth and makes it difficult to eat, speak, and swallow. The team will develop salivary gland tissues using a unique chip technology called “microbubbles,” which are tiny spherical wells or bubbles that can hold cells.
The use of the microbubble platform is based on several years of salivary gland research, led by Catherine E. Ovitt, Ph.D., associate professor of Biomedical Genetics, a member of the UR Center for Oral Biology, and an expert in the repair and regeneration of salivary glands, and Danielle Benoit, Ph.D., associate professor of Biomedical Engineering and an expert in drug delivery systems and hydrogel platforms for tissue engineering approaches. Together with Lisa A. DeLouise, Ph.D., associate professor of Dermatology and Biomedical Engineering, who developed and received several patents for the microbubble concept, the scientists are working as co-principal investigators on the NIH project.
Their goal is to find drugs that could be given to patients prior to radiation treatment that would prevent damage to the glands.
The team is collaborating with Shawn D. Newlands, M.D., Ph.D., M.B.A., chair of the Department of Otolaryngology and member of the Wilmot Cancer Institute’s head and neck oncology team, to collect salivary tissue from consenting patients undergoing salivary gland surgery. Salivary gland cells are isolated from these tissues for seeding into microbubbles for the investigation. Additionally, Paul Dunman, Ph.D., associate professor of Microbiology and Immunology, will provide high-throughput drug-screening expertise during the second phase of the project, which is contingent upon successful development of the human gland chips.
Read More: “Bubbles” Boost Search for Treatment to Aid Head and Neck Cancer Patients
URMC Otolaryngology Residency Program Matches Two Medical Students
The department is pleased to welcome incoming first-year residents Martha Luitje from the University of Massachusetts Medical School and Sheela Saidha from Eastern Virginia Medical School to the five-year Otolaryngology Residency Program.
Shawn Newlands Appointed Associate CMO for Ambulatory Care
In a move that reflects the importance of our expanding outpatient network, Shawn Newlands, M.D., Ph.D., M.B.A, has been appointed to the newly created role of Associate Chief Medical Officer for URMC’s ambulatory care enterprise.
URMC Otolaryngology Resident Receives Award for Presentation
Otolaryngology second-year resident Stephanie Wong won 1st place in pediatric otolaryngology for her poster presentation on the management of pediatric orbital cellulitis at the Triological Society's 2017 Combined Sections Meeting held in New Orleans, LA, January 19th-21st, 2017.